You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameCripto1 protein (Active)See all Cripto1 proteins and peptides ...
  • Protein descriptionRecombinant fragment, corresponding to amino acids 31-169 of Human Cripto1 (Swiss-Prot P13385) fused to the Fc region of human IgG1 (aa 90-330). The chimeric protein was expressed in modified human 293 cells.
  • Expression hostHEK 293 cells

    • Properties

  • Purity> 95 % by SDS-PAGE
  • Biological activity200 ng/ml of this Chimera induces ERK1 and ERK2 phosphorylation in human umbilical vein endothelial (HUVEC) cells.
  • FormLyophilised:It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial. Following reconstitution short-term storage at 4°C is recommended, with longer-term storage in aliquots at -18 to -20°C. Repeated freeze thawing is not recommended.
  • Storage instructionsShipped at 4°C. After reconstitution store at -20ºC. Avoid freeze / thaw cycles.This product is an active protein and may elicit a biological response in vivo, handle with caution.
  • Storage bufferPreservative: None
    Constituents: 10% Trehalose, 1% Human serum albumin
  • Concentration information loading...
  • Sequence notesTheoretical sequence: LGHQEFARPSRGYLAFRDDSIWPQEEPAI RPRSSQRVPPMGIQHSKEL NRTCCLNGGTCMLGSFCAC PPSFYGRNCEHDVRKENCGSVPHDTWLPK KCSLCKCWH GQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSGSSNT KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPP SRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK
  • Research Areas

    • Applications

    Our Abpromise guarantee covers the use of ab84062 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    SDS-PAGE
  • Application notesSDS-PAGE: Use at an assay dependent dilution.

    Under reducing conditions ab84062 migrates as a broad band between 45 and 55 kDa on SDS-PAGE due to post-translational modifications, in particular glycosylation. This compares with unmodified protein that has a predicted monomeric molecular mass of 42.8 kDa. ab84062 consists of 5-30% carbohydrate by weight.

    ab84062 separates into a number of glycoforms with an observed pI between 6.5 and 10 on 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified protein that has a predicted pI of 8.2.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Protein info

    • Alternative names
        CRCRGFcripto
        Cripto 1Cripto 1 growth factorCripto-1 growth factorCripto1Cripto1 growth factorEpidermal growth factor like cripto protein CR1Epidermal growth factor-like cripto protein CR1TDGF 1TDGF1TDGF1_HUMANTeratocarcinoma derived growth factor 1Teratocarcinoma-derived growth factor 1
      see all
  • FunctionCould play a role in the determination of the epiblastic cells that subsequently give rise to the mesoderm.
  • Tissue specificityPreferentially expressed in gastric and colorectal carcinomas than in their normal counterparts.
  • Sequence similaritiesContains 1 EGF-like domain.
  • Cellular localizationCell membrane.

    • Target information above from: UniProt accession P13385 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt

    Cripto1 protein (Active) images

    • SDS-PAGE - Cripto1 protein (Fc Chimera Active) (ab84062)
      SDS-PAGE - Cripto1 protein (Fc Chimera Active) (ab84062)
      Lane 1 – MW markers; Lane 2 – ab84062; Lane 3 – ab84062 treated with PNGase F to remove potential N linked glycans; Lane 4 – ab84062 treated with a glycosidase cocktail to remove potential N- and O-linked glycans. Approximately 5 µg of protein was loaded per lane; Gel was stained using Coomassie.

      Drop in MW after treatment with PNGase F indicates the presence of N-linked glycans. A further drop in MW after treatment with the glycosidase cocktail indicates the presence of O-linked glycans. Additional bands in lane 3 and lane 4 are glycosidase enzymes.
    • SDS-PAGE - Cripto1 protein (Fc Chimera Active) (ab84062)
      SDS-PAGE - Cripto1 protein (Fc Chimera Active) (ab84062)
      A sample of ab84062 without carrier protein was reduced and alkylated and focused on a 3-10 IPG strip then run on a 4 20% Tris-HCl 2D gel. Approximately 40 µg of protein was loaded; Gel was stained using Deep Purple™. The spot train indicates the presence of multiple glycoforms. Spots within the spot train were cut from the gel and identified as Cripto1 (Fc Chimera) by protein mass fingerprinting.
    • Functional Studies - Cripto1 protein (Fc Chimera Active) (ab84062)
      Functional Studies - Cripto1 protein (Fc Chimera Active) (ab84062)
      Post-translational modifications result in protein heterogeneity. The densitometry scan demonstrates the purified human cell expressed protein exists in multiple glycoforms, which differ according to their level of post-translational modification.

      The triangle indicates theoretical pI and MW of the protein.

    References for Cripto1 protein (Active) (ab84062)

    ab84062 has not yet been referenced specifically in any publications.

    Publishing research using ab84062 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab84062 Submit a Question for ab84062

    There are currently no Abreviews or Questions for ab84062.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"